Published in Cancer Weekly, May 23rd, 2000
"As approximately half of malignant gliomas exhibit p53 mutations, we are examining vaccine therapies for intracranial MethA, a methylcholanthrene-induced BALB/c mouse sarcoma that expresses a p53 mutation at codon 234," stated Timothy F. Witham, Pittsburgh, Pennsylvania, and colleagues from several institutions in the United States. "This peptide is processed and presented on H2-Kd molecules and recognized by CTLs."
Witham et al. presented data from their study at the 2000 Annual Meeting of the American...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.